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Abstract
Background: Lymphogranuloma venereum (LGV) proctitis is caused by Chlamydia trachomatis (Ct) genotype L and is
endemic among men who have sex with men (MSM) in western society. Genotype L infections need to be
distinguished from non-LGV (genotypes A-K) Ct infections since they require prolonged antibiotic treatment. For this
purpose, an in-house developed pmpH based LGV polymerase chain reaction (PCR) test is used at the Amsterdam STI
outpatient clinic. We investigated retrospectively the anal Ct genotype distribution, and the frequency of concomitant
genotype infections in MSM infected with LGV and non-LGV Ct infections. To detect concomitant Ct genotype
infections, the pmpH LGV PCR and genoTyping Reverse Hybridization Assay (Ct-DT RHA) were used.
Methods: A total of 201 Ct positive rectal swabs from MSM were selected, which were previously diagnosed as
either LGV (n = 99) or non-LGV Ct infection (n = 102) according to the algorithm of Ct detection by the
commercially available Aptima Combo 2 assay followed by an in-house pmpH LGV PCR. The samples were retested
with the commercially available Ct-DT RHA, which differentiates between 14 major genotypes and is able to detect
concomitant Ct genotypes.
Results: Excellent genotyping agreement was observed between the Ct-DT RHA and the pmpH LGV PCR (Kappa =
0.900, 95%CI = 0.845-0.955, McNemar’s p = 1.000). A concomitant non-LGV genotype was detected in 6/99 (6.1%)
LGV samples. No additional LGV infections were observed with the Ct-DT RHA among the non-LGV Ct group. In
the non-LGV group genotype G/Ga (34.3%) was seen most frequent, followed by genotype D/Da (22.5%) and
genotype J (13.7%). All LGV infections were caused by genotype L2.
Conclusions: Concomitant non-LGV genotypes do not lead to missed LGV proctitis diagnosis. The pmpH LGV PCR
displayed excellent agreement with the commercially available Ct-DT genotyping RHA test. The genotypes G/Ga,
D/Da and J were the most frequent non-LGV Ct strains in MSM.
Background
Chlamydia trachomatis (Ct) is the most common sexu-
ally transmitted bacterial disease worldwide. A Ct infec-
tion can infect different mucosal linings, with the
majority of cases in the urogenital tract but also the rec-
tum, oropharynx or conjunctiva.
In men who have sex with men (MSM), the rectum is
often the only infected site, without a concurrent Ct
infection in the urogenital tract [1]. Like urogenital
infections, most rectal Ct infections remain asympto-
matic [2]. Nevertheless, an asymptomatic rectal Ct infec-
tion can contribute to HIV transmission due to mucosal
damage and recruitment of dendritic cells [3].
In general, Ct infections caused by non-LGV Ct geno-
types (D-K) give few or no symptoms since they remain
confined to the mucosal lining and do not trigger overt
immunological reactions [4]. Ct infections caused by the
genotypes L1-L3 give rise to an invasive, symptomatic
and ulcerative infection called lymphogranuloma vener-
eum (LGV). Since 2004 an ongoing epidemic of LGV
* Correspondence: samorretravel@yahoo.co.uk
† Contributed equally
5The Department of Pathology, Laboratory of Immunogenetics, VU University
Medical Centre, Amsterdam, the Netherlands
Full list of author information is available at the end of the article
Quint et al. BMC Infectious Diseases 2011, 11:63
http://www.biomedcentral.com/1471-2334/11/63
© 2011 Quint et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.proctitis is affecting MSM in Western countries, of which
many are co-infected with HIV and hepatitis C [5]. It is
highly recommended to differentiate an LGV Ct infection
from a non-LGV Ct infection, since an LGV Ct infection
requires longer antibiotic treatment [6]. Nowadays sev-
eral assays are available to differentiate between an LGV
genotype and a non-LGV genotype [7-11].
At the sexually transmitted infections (STI) outpatient
clinic of the Public Health Service (MHS) of Amsterdam
all MSM engaging in receptive anal sex in the previous
6 months are screened for anal Ct infections by the
Aptima Combo 2 system (GEN-PROBE, San Diego,
USA) and, if Ct positive, further tested with a pmpH
based in-house developed real-time PCR to discriminate
between an LGV genotype and a non-LGV genotype [7].
The MSM population visiting STI clinics are often diag-
nosed simultaneously with multiple STIs [12]. It has
been suggested that in case of a mixed Ct infection with
both LGV and non-LGV genotypes, a low bacterial load
of the LGV genotype could be missed due to primer
competition for different genotypes [13].
The genotyping step from the Ct-Detection and geno-
Typing (DT) assay (Labo Biomedical Products BV, Rijs-
wijk, The Netherlands) can simultaneously genotype
multiple Ct genotypes (A, B/Ba, C, D/Da, E, F, G/Ga, H, I/
Ia, J, K, L1, L2/L2a, and L3) by a dual target PCR, targeting
OmpA and the Ct endogenous plasmid, followed by a
reverse hybridization assay (RHA) [8,14]. This RHA plat-
form can detect concomitant infections, even if one geno-
type is present in a much lower concentration compared
to additional genotypes (up to ratios of 1:1000) [15].
In the current study, we evaluated the diagnostic per-
formance of the pmpH LGV PCR, used at the MHS of
Amsterdam for the diagnosis of LGV infections, by
retesting 100 LGV Ct positive and 100 non-LGV Ct
positive samples with the Ct-DT RHA PCR system. In
addition, we investigate the anal concomitant Ct geno-
type infections. Finally, we studied the non-LGV geno-
type distribution in rectal samples from MSM.
Methods
Clinical specimens
In the STI clinic of the Public Health Service of Amster-
dam non-LGV Chlamydia and LGV infections in anal
samples of MSM are diagnosed according to an algo-
rithm consisting of Ct detection with the Aptima
Combo 2 test, followed by differentiation with the
pmpH LGV PCR, briefly described below. We selected
samples from the archive (-80ºC freezer) of the Public
Health Laboratory from a period starting in December
2009 and going back in time, until we had about 100
LGV samples and about 100 non-LGV Ct samples, as
described before [16]. Since the prevalence of LGV Ct
infections among clients of the STI clinic is much lower
than the prevalence of non-LGV Ct infections, the per-
iod from which the LGV positive samples were selected
was longer than the period from which the non-LGV
samples were selected. Participants with non-LGV proc-
titis were treated with doxycycline 100 mg twice daily
for a minimum of 7 days and those with LGV proctitis
for a minimum of 21 days, directly after diagnosis. For
this study we did not use any additional data or samples
other than obtained in the routine screening procedure
of the clinic. Therefore, neither additional ethical
approval, nor additional patient consent was considered
necessary. All samples were de-identified before starting
the analyses. No history about the patient’sS T Da n d
HIV status was available.
Algorithm of Ct detection and LGV differentiation for
rectal swabs from MSM visiting the STD clinic from the
MHS
Rectal swabs from MSM were first tested for Ct with the
commercially available Aptima Combo 2 Ct-RNA TMA
assay, according to the manufacturer’s instruction (GEN-
PROBE, San Diego, USA). All Ct positive samples were
further tested with the in-house pmpH LGV real time
PCR, of which the primers and probes were described
previously [7]. Briefly, the real time PCR was performed
in 20 μL, containing Platinum Quantitative PCR Super-
Mix-UDG (Invitrogen, Breda, the Netherlands), 2 μLo f
isolated DNA, 4.3 mM MgCl2,0 . 4 0μMo fp r i m e rF 3
LGV, 0.39 μMo fp r i m e rF 4n o n - L G Va n d0 . 9 2μMo f
primer R2 LGV/non-LGV, 0.15 μM of probe LGVtotP
and 0.21 μM of probe P4 non-LGV. Cycling conditions
for the real-time PCR were: uracil DNA glycosylase step
at 50ºC for 2 minutes and denaturation at 95ºC for 2 min-
utes, followed by 45 cycles of 15 seconds at 95ºC and
1 minute at 60ºC. All tests were performed on a Rotor-
Gene 6000 (Qiagen, Venlo, the Netherlands). Samples
that were negative with the pmpH real time PCR were
considered to be non-LGV Ct infection, since the sample
was already determined Ct positive with the more sensi-
tive Aptima Combo 2 assay.
DNA isolation
Isolation of the DNA was performed at the MHS. DNA
was isolated from 200 μl transport medium (GEN-
PROBE, San Diego, USA) by adding 500 μll y s i s b u f f e r
(bioMérieux, Boxtel, the Netherlands), 1 μlg l y c o g e n
(20 mg/mL, Roche Diagnostics, Almere, the Nether-
lands) and 700 μL isopropanol (-20ºC). The precipitate
was washed twice with 70% ethanol and subsequently
dissolved in 50 μl 10 mM Tris buffer (pH 8.0).
Ct-DT RHA
The Ct-DT PCR and Ct-DT RHA were performed
according to the manufacturer’s instructions (Labo
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as described previously [8,17]. No Ct-DT detection with
aC t - D N Ae n z y m ei m m u n o a s s a yw a sp e r f o r m e d
between the amplification and genotyping step, since all
samples were already previously determined as Ct posi-
tive by the Aptima Combo 2 assay.
Ct-DT PCR: A1 0μl aliquot of extracted DNA was
used for each PCR reaction. The Ct PCR primer set was
used to amplify all known genotypes available in Gen-
Bank http://www.ncbi.nlm.nih.gov/genbank. Briefly, this
multiplex primer set amplifies a small fragment of 89
base pairs from the endogenous plasmid and a fragment
of 160/157 base pairs from the Variable Region 2 of the
ompA gene. The standard PCR program involves a
9-minute preheating step at 94ºC for AmpliTaq Gold
activation, followed by 40 cycles of amplification (30 sec-
onds at 94ºC, 45 seconds at 55ºC and 45 seconds at
72ºC) and a final 5-minute elongation at 72ºC.
Ct-DT Reverse Hybridization Assay (RHA): The Ct-DT
RHA contained 19 probes for the endogenous plasmid,
the Ct serogroups (B, C, and I) and the 14 genotypes
( A ,B / B a ,C ,D / D a ,E ,F ,G / G a ,H ,I / I a ,J ,K ,L 1 ,L 2 / L 2 a ,
and L3). Genovar L2b is detected as L2. The probe for
the endogenous plasmid was added to increase sensitiv-
ity for Ct-detection, since genotyping on the plasmid is
not possible. In short, 10 μl of the biotin-labeled PCR
product was mixed with 10 μl of denaturation solution
and incubated at 50°C for 1 hour, followed by several
washing steps. All incubations and washing steps were
performed automatically in an AutoLipa instrument
(Tecan Austria GmbH, Salzburg, Austria).
Statistical analysis
The level of agreement between the pmpH LGV PCR
and the Ct-DT RHA was determined using Cohen’s
Kappa for four categories. A two-tailed McNemar’s
test was performed to investigate differences between
both assays. The level of statistical significance was set
at p < 0.05. All statistical analyses were performed in
SPSS version 17.0 (SPSS version 17.0; Gorinchem, the
Netherlands). Serovar distribution analysis was per-
formed in each group separately, since the LGV and
non-LGV Ct infections were obtained consecutively
during different time frames.
Results
Agreement between the Ct-DT RHA and the pmpH
LGV PCR
An excellent agreement was observed between the
Ct-DT RHA and the pmpH LGV PCR in differentiating
between an LGV and a non-LGV Ct infection (Kappa
value = 0.900, 95% CI = 0.845 - 0.955, McNemar’sp=
1.000) (Table 1). 189/201 (94%) samples showed diag-
nostic concordance between the two assays, consisting
of 91 LGV infections, 82 non-LGV infections, 4 mixed
LGV/non-LGV infections and 12 non-typable infections
(yet 6/12 of these non-typable samples were still Ct
plasmid positive with the Ct-DT RHA). A total of 12
(6%) discordant samples were observed. The discordant
samples between both assays consisted of 2 infections
that were diagnosed as LGV with the pmpH LGV PCR,
b u td e t e r m i n e da sam i x e dL G V / n o n - L G Vi n f e c t i o n
with the Ct-DT RHA and also 2 infections were deter-
mined as LGV infection with the Ct-DT RHA, but diag-
nosed as mixed LGV/non-LGV infection with the pmpH
LGV PCR. Four Ct infections diagnosed as non-typable
with the pmpH LGV PCR, were determined as a non-
LGV Ct infection with the Ct-DT RHA, and vice versa 4
samples were non-typable (3 Ct endogenous plasmid Ct
positive and 1 Ct negative) with the Ct-DT RHA but
diagnosed as non-LGV Ct infection with the pmpH
LGV PCR. All 99 LGV infections were confirmed with
the Ct-DT RHA and no additional LGV infections were
observed in the non-LGV group.
Ct genotype distribution
The Ct-DT RHA was used to investigate the genotype
distribution among the 201 rectal samples. All 99 LGV
Ct infections consisted of genotype L2. Six of these 99
patients had a co-infection with a non-LGV Ct strain:
D/Da (n = 2), E (n = 2), G (n = 1) and J (n = 1).
Among the non-LGV Ct infections in MSM, genotype
G/Ga (34.3%) was most prevalent, followed by genotype
D/Da (22.5%) and genotype J (12.7%) (Table 2). One
concomitant genotype infection was observed in the
non-LGV group, containing the genotypes E&F. A trend
toward significance was observed for concomitant infec-
tions with a LGV type compared to concomitant non-
LGV genotype infections (6.1% vs. 1.0%, Fisher’se x a c t
p = 0.1244).
Table 1 Genovar differentiation results of the pmpH real
time PCR and the Ct-DT RHA of 201 Aptima combo 2
C. trachomatis positive rectal swabs from men who have
sex with men visiting the Amsterdam STI clinic between
August 2008 and December 2009
pmpH LGV PCR
Ct-DT RHA LGV Non-LGV LGV+non-LGV Non-typable* Total
LGV 91 - 2 - 93
Non-LGV - 82 - 4 86
LGV+non-LGV 2 - 4 - 6
Non-typable* - 4 - 12 16
Total 93 86 6 16 201
Overall Kappa value = 0.900 (95% CI = 0.845 - 0.955), McNemar’s p = 1.000.
* The Ct-DT RHA non-typable samples consist of 9 Ct endogenous plasmid
positive samples and 7 Ct negative samples. All 16 non-typable samples with
the pmpH LGV PCR showed a negative result.
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The Ct-DT RHA and the pmpH LGV PCR showed an
excellent agreement in differentiating between an LGV
and a non-LGV Ct infection. No additional LGV infec-
tions were observed with the Ct-DT RHA, indicating a
good diagnostic performance of the pmpH LGV PCR for
the detection of LGV infections. Still 2 concomitant
non-LGV infections were missed with both assays
among the LGV group. This discrepancy might be due
to a lower bacterial load of the non-LGV Ct infection in
the isolated DNA and/or primer competition during the
PCR. However, this observation has no clinical rele-
vance, since all patients received treatment for an LGV
infection, which is more than sufficient for a non-LGV
infection. It would be of more importance when conco-
mitant LGV infections were missed, but fortunately this
was not the case.
The current study showed that 1.0% of the Ct infec-
tions within the non-LGV group consisted of a conco-
mitant non-LGV infection. This study also provides an
estimate of the prevalence of non-LGV co-infections
(6.1%) among MSM infected with LGV. The results of
concomitant genotypes in both groups are comparable
with previous studies of the urogenital tract in the gen-
eral population, although the percentage in the non-
LGV group seems slightly lower [18-22].
The Ct-DT RHA not only differentiates between an
LGV and non-LGV Ct infection, but is also able to
further differentiate between the 14 major Ct genotypes.
The most frequently observed Ct genotypes were the
genotypes G/Ga, D/Da and J in the non-LGV group.
This distribution is similar to the distributions found in
rectal samples from other MSM studies performed pre-
viously at different time periods (1987 to 2010) and dif-
ferent geographic locations (North America, Europe and
A u s t r a l i a ,F i g u r e1 )[ 2 3 - 2 8 ] .O n l yo n es t u d y( t h e
Netherlands) showed discordant results, as genotype J
was totally absent and a high number of genotype H
was present [27]. In that study the RFLP technique was
used to discriminate between the genotypes. As the
RFLP patterns of genotype H and J are very similar, it is
possible that in that study the J genotypes might have
been mistaken for H genotypes.
The anal genotype distribution in MSM, dominated
by types G, D and J, differs significantly from the distri-
bution found in genital samples from the heterosexual
population, where E, F, and D are the most frequently
observed genotypes [14,29-31]. Apart from network
associated factors, also tissue tropism could explain this
difference in distribution, certainly since a recent study
revealed an association between rectal tropism and
polymorphisms of open reading frames within genotype
G [32]. Also, on rectal swabs from heterosexual women
an elevated prevalence of genotype G/Ga compared to
urogenital samples was found, although this was not
significant [33].
All LGV infections were caused by genotype L2. Pre-
vious sequencing identified the Ct genovariant L2b,
which is a genovariant of genotype L2 [7]. This genotype
is highly specific for LGV proctitis in the current epi-
demic among MSM, while during the 1980s-1990 s also
genotype L1 was described among MSM [34].
Conclusion
The Ct-DT RHA and the pmpH LGV PCR had an
excellent agreement in differentiating LGV from non-
LGV Ct infections. Also, concomitant non-LGV geno-
types do not lead to missed LGV proctitis diagnosis
with the pmpH LGV PCR. The anogenital genotype G/
Ga, D/Da and J were the most frequent genotypes in
rectal samples from MSM infected with a non-LGV
strain. This genotype distribution differs from that of
Table 2 Genotype distribution of the 102 non-LGV
positive rectal swabs from MSM visiting the Amsterdam




Genotype D/Da 23 22.5
Genotype E 7 6.9
Genotype F 5 4.9
Genotype G/Ga 35 34.3
Genotype J 14 13.7
Genotype K 1 1.0
Non-typable 16 15.7
Mixed infections
Genotypes E&F 1 1.0
Total 102 100
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Figure 1 Rectal non-LGV Ct genotype distribution in men who
have sex with men: a comparison with previous studies
[23,24,27,28]. Non typable infections in the non-LGV group were
excluded.
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infections were caused by genotype L2, which is in line
with previous observations among MSM.
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